T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Active, not recruiting · NCT02326974 · Registry updated 2026-10-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-10-02 | NCT02326974 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Dana-Farber Cancer Institute | 324 |
| Genentech, Inc. | 221 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana Farber Cancer Institute | Boston | United States | 300 |
| Massachusetts General Hospital | Boston | United States | 1015 |
| Tennessee Oncology/Sarah Cannon Research Institute | Nashville | United States | 1 |
| Vanderbilt-Ingram Cancer Center | Nashville | United States | 48 |